Literature Review of 141 Cases of Adverse Drug Reactions Induced by Simvastatin

Abstract

Abstract: Objective To provide references for the safe and rational use of simvastatin in clinic through investigating the characteristics of adverse drug reactions (ADRs) induced by this drug. Methods Using "simvastatin", "adverse reaction" as key words to search and retrieve articles in the CNKI database, WanFang database and VIP Chiese full-text database. The literature was analyzed according to the inclusion and exclusion criteria. Results A total of 123 papers, 141 cases were included. Systems and organs mainly involved in ADRs were musculo-skeletal system disorders and liver and biliary system disorders. ADRs occurred most frequently within 90 days of medication. Conclusion It is important for clinicians and patients to make aware of simvastatin-induced ADRs. Supervision and precaution should be strengthened in the clinical use of simivastatin.

Key words: simvastatin, adverse drug reactions, literature review

CLC Number:

R994.11

ZHANG Xuan, GU Yunxia*. Literature Review of 141 Cases of Adverse Drug Reactions Induced by Simvastatin[J]. Chinese Journal of Pharmacovigilance, 2019, 16(8): 487-491.

References

[1] Rosenson R S, Baker S K, Jacobson T A, et al.An assessment by the Statin Muscle Safety Task Force: 2014 update[J]. Journal of Clinical Lipidology, 2014, 8(3):S58-S71.
[2] 高千秋, 张浩嘉. 302例他汀类药物相关肌肉系统损害的文献分析[J]. 中国药物警戒, 2018, 15(8):476-480.
[3] 国家药品不良反应监测中心. 药品不良反应报告和监测工作手册[EB/OL]. (2012-11)[2019-04-22]. http://www.cdr-adr.org.cn/xzzx/hyzl/hyzl2013nd/201304/t20130426_5436.html.
[4] 刘晓凯. 辛伐他汀致肌病及急性肾功能不全一例报告[J].浙江临床医学, 2006,8(1): 85.
[5] 杜娟. 辛伐他丁致横纹肌溶解综合征1例[J].中国临床药学杂志, 2011, 20(6): 378.
[6] 金旭明, 刘翠芹.辛伐他汀致严重肝脏损害久治不愈一例[J].中国疗养医学, 2011. 20(7): 655.
[7] 林玳. 辛伐他汀与环孢素合用引起横纹肌溶解案例分析[C]//2012年浙江省医学会临床药学学术年会暨医院药事管理质控中心.临床药学分会十周年庆典大会论文集. 杭州:2012:462-464.
[8] 中国老年医学研究会内分泌代谢分会, 中国毒理学会临床毒理专业委员会. 老年人多重用药安全管理专家共识[J]. 中国药物警戒, 2018, 15(10):55-68.
[9] 国家药品监督管理局药品评价中心. 警惕辛伐他汀与胺碘酮联合使用或高剂量使用增加横纹肌溶解发生风险[EB/OL]. (2010-11-16)[2019-03-29]. http://samr.cfda.gov.cn/WS01/CL1989/55959.html.
[10] FDA. Drug Safety Communication: New restrictions, contraindications,dose limitations for Zocor (simvastatin) to reduce the risk of muscle injury[EB/OL]. (2011-06-08)[2019-03-29]. https://www.fda.gov/Drugs/DrugSafety/ucm256581.htm.
[11] Francois Mach, Kausik K Ray, Olov Wiklund, et al.Adverse effects of statin therapy: perception vs. the evidence -focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract[J]. European Heart Journal, 2018, 39(27): 2526-2539.
[12] 诸骏仁, 高润霖, 赵水平, 等. 中国成人血脂异常防治指南(2016年修订版)[J]. 中国循环杂志, 2016, 16(10):15-35.
[13] Sakamoto K, Kimura J.Mechanism of Statin-Induced Rhabdomyolysis[J]. Journal of Pharmacological Sciences, 2013, 123(4):289-294.
[14] 李昂, 张冰, 张晓朦, 等. 1109所基层医疗机构的药品不良反应认知及呈报情况调研[J]. 中国药物警戒, 2017. 14(5):289-294.

[1]	CAO Guiping, DENG Linlin, ZHU Ganhong, LU Ying, MA Shuang, CHEN Linlin, Liu Lili. One case of severe liver injury caused by Tianma Shouwu tablets [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 216-218.
[2]	GUO Longxin, GAO Yunjuan, WU Chengzhao, LONG Minjuan, ZHU Shengkai, SONG Haibo, ZHAO Xu, XIAO Xiaohe. Exploring new risk signals and susceptibility factors of traditional Chinese medicine-induced hepatotoxicity based on big data from adverse reaction monitoring [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 15-19.
[3]	JIANG Wenshuo, YANG Li. Adverse drug reaction among 694 patients in an epilepsy physician-pharmacist joint clinic [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 102-106.
[4]	CHEN Huayan, JIANG Dongbo, GUO Chunlian, YANG Jiaqi, LI Yuxin, CAI Weiming. Safety of nirmatrelvir/ritonavir in the treatment of novel coronavirus infections [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 107-110.
[5]	LI Xiaozhu, WANG Qiang, PANG Yu, ZHANG Yijing. Management of individual adverse drug reaction reports [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 975-977.
[6]	LIU Wendong, CUI Huanhuan, WANG Xiaohan, SU Xian, WANG Haixue. Status and thinking of Parmacovigilance regulatory system during clinical trials of the pediatric drug in China [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1002-1006.
[7]	ZANG Tianying, LIU Bingyang, TANG Xiaojun. Differentiation of vancomycin induced anaphylactoid and anaphylactic reactions [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1078-1080.
[8]	CHANG Yongzhuo, LI Ji, ZHANG Xiaoyan, ZHOU Chaofan. One case of abnormal uterine bleeding caused by Baofukang suppository [J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 935-938.
[9]	WANG Shuwei, YIN Jinjun, WANG Bing, SONG Caiping, YANG Fujun. Axitinib tablets combined with toripalimab injection in the treatment of renal cancer-induced central retinal artery occlusion: a case report [J]. Chinese Journal of Pharmacovigilance, 2023, 20(7): 825-828.
[10]	ZHENG Yi, LUO Xiao, ZHANG Pengpeng, LIU Yongmei, YE Xiaofei, GUO Xiaojing, CHEN Xia, HE Jia. Adverse reactions of immune checkpoint inhibitor myocarditis based on active monitoring system [J]. Chinese Journal of Pharmacovigilance, 2023, 20(6): 634-638.
[11]	LI Tan, ZHANG Yang, ZHANG Wangde, WANG Yun. Efficacy and safety of different analgesia drugs in the treatment of lower extremity ischemic pain [J]. Chinese Journal of Pharmacovigilance, 2023, 20(6): 680-683.
[12]	CHEN Chongze, LI Jie, KUANG Lian, TAN Xuewen, LIU Minhui, LIU Xi, ZHENG Yanchai, JIN Hongtao. Characterization of adverse reactions associated with drug-induced liver injury in 448 inpatients [J]. Chinese Journal of Pharmacovigilance, 2023, 20(6): 697-704.
[13]	. Annual report of national adverse drug reaction monitoring (2022) [J]. Chinese Journal of Pharmacovigilance, 2023, 20(6): 712-719.
[14]	CHEN Cheng, DENG Li, LIU Songqing, DU Qian, XI Xin. Analysis of reports of allergic shock in Chongqing between 2015 and 2020 [J]. Chinese Journal of Pharmacovigilance, 2023, 20(4): 460-464.
[15]	OUYANG Ying, ZHONG Changxin, XIA Chunhua, NIE Jungang, ZHOU Ying. One case of breast hyperplasia caused by digoxin tablets [J]. Chinese Journal of Pharmacovigilance, 2023, 20(3): 346-347.